Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C.
Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C.
复制标题
DOI：
10.1093/ofid/ofu110
复制
发表时间：
2014-12
影响因子：
4.2
通讯作者：
Pfeiffer RM
中科院分区：
文献类型：
--
作者：
O'Brien TR;Lang Kuhs KA;Pfeiffer RM
使用雷迪帕韦/索非布韦治疗丙型肝炎病毒（HCV）感染有望带来巨大益处，但高昂的费用可能会阻碍该方案的实施。对8周治疗反应良好的亚组可能对较短疗程有反应。在ION - 3研究中，423名先前未接受过治疗的感染丙型肝炎病毒基因1型且无肝硬化的患者在接受雷迪帕韦/索非布韦治疗8周后有了结果数据。在重新分析已发表的ION - 3数据后，我们发现持续病毒学应答（SVR）率因性别（P = 0.002）和rs12979860基因型（趋势P = 0.03）而有显著差异，女性和rs12979860 - CC型个体的持续病毒学应答率超过98%。这些亚组中非常高的持续病毒学应答率表明，在选择接受8周雷迪帕韦/索非布韦治疗的患者时可以考虑这些因素，并支持在选定患者中对该方案进行更短疗程的试验。
Treatment of hepatitis C virus (HCV) infection with ledipasvir/sofosbuvir promises tremendous benefits, but high cost may impede implementation of this regimen. Subgroups with excellent response to 8 weeks of treatment might respond to a shorter course. In ION-3, 423 previously untreated HCV genotype 1-infected patients without cirrhosis had outcome data after receiving ledipasvir/sofosbuvir for 8 weeks. After reanalyzing published ION-3 data, we found that sustained virologic response (SVR) rates varied significantly by gender (P = .002) and rs12979860 genotype (Ptrend = .03), exceeding 98% in women and rs12979860-CC individuals. The very high SVR rates in these subgroups suggest that these factors might be considered in selecting patients to receive 8 weeks of ledipasvir/sofosbuvir and support shorter trials of this regimen in selected patients.